Drug Trial Radar · NCT06574347
Vebreltinib Plus PLB1004 as the First-line Therapy for Patients With EGFRm+/MET+ Locally Advanced or Metastatic NSCLC.
Last checked: Nov 19, 2026Latest source record: May 21, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
120
Planned (sponsor's estimate)
Start
Aug 7, 2024
Primary completion
Oct 31, 2026
Study completion Jul 31, 2027
Sponsor
- Lead sponsor
- Avistone Biotechnology Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Aug 27, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Efficacy and Safety Evaluation of Vebreltinib Plus PLB1004 as the First-line Therapy for Patients With EGFRm+/MET+ Locally Advanced or Metastatic NSCLC.
Conditions
- Non-Small-Cell Lung Cancer
Interventions
VebreltinibDrug
Subjects will receive Vebreltinib orally twice per day (BID).
OsimertinibDrug
Subjects will receive Osimertinib 80mg orally once per day (QD).
PLB1004Drug
Subjects will receive PLB1004 80mg orally once per day (QD).
Primary outcomes
What the sponsor says the trial is designed to measure.
- The objective response rate of the tumor (ORR)Time frame: 2 Years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Guangdong Provincial People's Hospital
Guangzhou, Guangdong, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.